急诊就诊涉及致幻剂使用与精神分裂症谱系障碍风险
这项基于加拿大安大略省人群的回顾性队列研究纳入9244292名14至65岁无精神病史个体,中位随访5.1年。涉及致幻剂使用的急诊就诊者3年内精神分裂症谱系障碍诊断风险显著高于一般人群(HR 3.53)及酒精(HR 4.66)或大麻(HR 1.47)相关急诊就诊者。
要点
- 涉及致幻剂使用的急诊就诊者3年内SSD绝对比例为3.99%,一般人群为0.15%。
- 完全调整后,致幻剂急诊就诊者SSD风险仍高于一般人群(HR 3.53)。
- 致幻剂急诊就诊者SSD风险高于酒精(HR 4.66)和大麻(HR 1.47)急诊就诊者。
核心结论
- 涉及致幻剂使用的急诊就诊者发生精神分裂症谱系障碍的风险高于一般人群及其他物质相关急诊就诊者。
- 鉴于致幻剂使用及相关急诊就诊增加,这些发现具有重要的临床和政策意义。
研究设计与样本
- 基于人群的回顾性队列研究,2008年1月至2021年12月纳入加拿大安大略省所有14至65岁无精神病史个体。
- 暴露为涉及致幻剂使用的首次急诊就诊,主要结局为经病历验证算法诊断的精神分裂症谱系障碍。
- 采用病因别调整风险模型估计关联,主要分析比较一般人群,次要分析比较酒精或大麻相关急诊就诊者。
- 共纳入9244292名个体,平均年龄40.4岁(SD 14.7),女性占50.2%,中位随访5.1年(IQR 2.3-8.6年)。
主要发现
- 5217名(0.1%)个体有涉及致幻剂使用的首次急诊就诊。
- 涉及致幻剂使用的急诊就诊年发生率2008至2012年间稳定,2013至2021年间上升86.4%(每10万人3.4 vs 6.4)。
- 与一般人群相比,致幻剂急诊就诊者3年内SSD风险更高(年龄和性别调整HR 21.32,95%CI 18.58-24.47);3年SSD绝对比例:致幻剂使用组5217人中208人(3.99%),一般人群9239075人中13639人(0.15%)。
- 调整共病物质使用和精神健康状况后,致幻剂急诊就诊者SSD风险仍高于一般人群(HR 3.53,95%CI 3.05-4.09)。
- 完全调整模型中,致幻剂急诊就诊者3年内SSD风险高于酒精相关急诊就诊者(HR 4.66,95%CI 3.82-5.68)和大麻相关急诊就诊者(HR 1.47,95%CI 1.21-1.80)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Interest in and use of hallucinogens has been increasing rapidly. While a frequently raised concern is that hallucinogens may be associated with an increased risk of psychosis, there are limited data on this association. OBJECTIVES: To examine whether individuals with an emergency department (ED) visit involving hallucinogen use have an increased risk of developing a schizophrenia spectrum disorder (SSD). DESIGN, SETTINGS, AND PARTICIPANTS: This population-based, retrospective cohort study (January 2008 to December 2021) included all individuals aged 14 to 65 years in Ontario, Canada, with no history of psychosis (SSD or substance induced). Data were analyzed from May to August 2024. EXPOSURE: An incident ED visit involving hallucinogen use. MAIN OUTCOMES AND MEASURES: Diagnosis of SSD using a medical record-validated algorithm. Associations between ED visits involving hallucinogens and SSD were estimated using cause-specific adjusted hazard models. Individuals with an incident ED visit involving hallucinogens were compared with members of the general population (primary analysis) or individuals with ED visits involving alcohol or cannabis (secondary analysis). RESULTS: The study included 9 244 292 individuals (mean [SD] age, 40.4 [14.7] years; 50.2% female) without a history of psychosis, with a median follow-up of 5.1 years (IQR, 2.3-8.6 years); 5217 (0.1%) had an incident ED visit involving hallucinogen use. Annual rates of incident ED visits involving hallucinogens were stable between 2008 and 2012 and then increased by 86.4% between 2013 and 2021 (3.4 vs 6.4 per 100 000 individuals). Individuals with ED visits involving hallucinogens had a greater risk of being diagnosed with an SSD within 3 years compared with the general population (age- and sex-adjusted hazard ratio [HR], 21.32 [95% CI, 18.58-24.47]; absolute proportion with SSD at 3 years, 208 of 5217 with hallucinogen use [3.99%] vs 13 639 of 9 239 075 in the general population [0.15%]). After adjustment for comorbid substance use and mental health conditions, individuals with hallucinogen ED visits had a greater risk of SSD compared with the general population (HR, 3.53; 95% CI, 3.05-4.09). Emergency department visits involving hallucinogens were associated with an increased risk of SSD within 3 years compared with ED visits involving alcohol (HR, 4.66; 95% CI, 3.82-5.68) and cannabis (HR, 1.47; 95% CI, 1.21-1.80) in the fully adjusted model. CONCLUSIONS AND RELEVANCE: In this cohort study, individuals with an ED visit involving hallucinogen use had a greater risk of developing an SSD compared with both the general population and with individuals with ED visits for other types of substances. These findings have important clinical and policy implications given the increasing use of hallucinogens and associated ED visits.
引用
- Myran DT, Pugliese M, Xiao J, et al. Emergency Department Visits Involving Hallucinogen Use and Risk of Schizophrenia Spectrum Disorder. JAMA Psychiatry. 2025. PMID: 39535804. doi:10.1001/jamapsychiatry.2024.3532
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。